Cipla to launch ayurveda and homeo products in India
BS Reporter / Mumbai/ Ahmedabad October 30, 2009, 0:09 IST
Pharmaceutical major Cipla India Ltd., under the brand name of its associate, L`amar Natural Products Pvt Ltd, will launch ayurvedic, homeopathic and cosmetic products in India in the coming months. The company, which launched its baby products recently, is in the process of research and development on its ayurvedic product, which includes diabetic capsules and the richest antioxidant, according to Ashok Naik, national sales manager — OTC division Cipla India Ltd.
After exporting various products all these years Cipla, under the brand name of its sister concern, L`amar, is planning to introduce natural products, homeopathic products, cosmetics and perfumes in the Indian market soon. While 20 products will be launched under cosmetics segment by January, 40 and 25 products will be launched under ayurvedic and homeopathic segments, respectively. The company is conducting an R&D on ayurveda diabetes capsules and the richest antioxidant on earth, made out of vegiberries found in China, parts of Tibet, Mongolia and the Himalayas. We are the pioneers of preparing antioxidants out of the vegiberry dryfruit and will launch the products in the next three to four months," Naik said, at a press meet in Ahmedabad to launch the company`s baby care products in Gujarat.
The five baby care products, which include baby oil, powder, soap, lotion and gripe water, will be marketed under platinum marketing, all India business partner for OTC product of Cipla India. The company also plans to launch a cough syrup, pain relief balm, anti-lice lotion and two baby food products in a month.
"The company expects a market share of Rs 40 crore from the over Rs 2,000 crore baby care products market in India and Rs 15 lakh per month from Gujarat. In order to retain its image as a pharma company, Cipla has decided to launch the products under the Rs 1500 crore Paris-headquartered L`amar", Naik added. Currently L`amar exports products to various markets in the Middle East, south East Asia, Africa, Latin America, Australia and Europe.
Cipla recorded an 82 per cent rise in its net profit for the July-September quarter this fiscal.
Though you are right as far as Hajj stats are concerned and its consequences, i advise the traders not to enter at the moment, as the govt stock piled many other drugs which are equally efficient and effective in fighting virus. Further 82 per cent raise is only holding price, otherwise, in the current correction, the price would have been 140 level. watch out for melt to-day
| NIFTY 
